
Pavel B Kopnin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3390814/publications.pdf Version: 2024-02-01



DAVEL R KODNIN

#	Article	lF	CITATIONS
1	Age-Related Changes in the Fibroblastic Differon of the Dermis: Role in Skin Aging. International Journal of Molecular Sciences, 2022, 23, 6135.	1.8	13
2	Molecular Mechanisms of Changes in Homeostasis of the Dermal Extracellular Matrix: Both Involutional and Mediated by Ultraviolet Radiation. International Journal of Molecular Sciences, 2022, 23, 6655.	1.8	14
3	Impaired Expression of Cytoplasmic Actins Leads to Chromosomal Instability of MDA-MB-231 Basal-Like Mammary Gland Cancer Cell Line. Molecules, 2021, 26, 2151.	1.7	1
4	Effect of caveolin-1 knockdown on the protein composition of extracellular vesicles secreted by non-small cell lung cancer cells. Uspehi Molekularnoj Onkologii, 2021, 8, 41-46.	0.1	0
5	The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site. Molecules, 2021, 26, 5780.	1.7	12
6	Inhibition of FGF2-Mediated Signaling in GIST—Promising Approach for Overcoming Resistance to Imatinib. Cancers, 2020, 12, 1674.	1.7	10
7	Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo. Anti-Cancer Drugs, 2019, 30, 475-484.	0.7	5
8	Spontaneous γH2AX foci in human dermal fibroblasts in relation to proliferation activity and aging. Aging, 2019, 11, 4536-4546.	1.4	14
9	Notch signaling pathway: dual role in tumour progression and therapeutic opportunities for bladder cancer. Onkourologiya, 2019, 15, 108-116.	0.1	0
10	Divergent impact of actin isoforms on cell cycle regulation. Cell Cycle, 2018, 17, 2610-2621.	1.3	18
11	Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo. Molecules, 2018, 23, 2643.	1.7	19
12	Mitochondria-targeted antioxidant SkQ1 suppresses fibrosarcoma and rhabdomyosarcoma tumour cell growth. Cell Cycle, 2018, 17, 1797-1811.	1.3	24
13	The role of skeletal muscle tissue extracellular matrix components in myogenesis. Genes and Cells, 2018, 13, 17-23.	0.2	0
14	Clinical-instrumental and morphological evaluation of the effect of autologous dermal fibroblasts administration. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 778-786.	1.3	14
15	Myogenic potential of human alveolar mucosa derived cells. Cell Cycle, 2017, 16, 545-555.	1.3	12
16	Components of the hepatocellular carcinoma microenvironment and their role in tumor progression. Biochemistry (Moscow), 2017, 82, 861-873.	0.7	88
17	Diffuse colonies of human skin fibroblasts in relation to cellular senescence and proliferation. Aging, 2017, 9, 1404-1413.	1.4	28
18	γH2AX, 53BP1 and Rad51 protein foci changes in mesenchymal stem cells during prolonged X-ray irradiation. Oncotarget, 2017, 8, 64317-64329.	0.8	31

Pavel B Kopnin

#	Article	IF	CITATIONS
19	Gingiva as a source of stromal cells with high differentiating and reparative potential. Genes and Cells, 2017, 12, 37-51.	0.2	2
20	Effects of autologous gingiva-derived cells with myogenic potential on regeneration of skeletal muscle. Genes and Cells, 2017, 12, 71-81.	0.2	0
21	E-Cadherin repression increases amount of cancer stem cells in human A549 lung adenocarcinoma and stimulates tumor growth. Cell Cycle, 2016, 15, 1084-1092.	1.3	30
22	Interaction of microtubules with the actin cytoskeleton via cross-talk of EB1-containing +TIPs and Î ³ -actin in epithelial cells. Oncotarget, 2016, 7, 72699-72715.	0.8	32
23	Tumor promotion by \hat{I}^3 and suppression by \hat{I}^2 non-muscle actin isoforms. Oncotarget, 2015, 6, 14556-14571.	0.8	50
24	Bioceramics Composed of Octacalcium Phosphate Demonstrate Enhanced Biological Behavior. ACS Applied Materials & Interfaces, 2014, 6, 16610-16620.	4.0	85
25	Octacalcium phosphate ceramics combined with gingiva-derived stromal cells for engineered functional bone grafts. Biomedical Materials (Bristol), 2014, 9, 055005.	1.7	32
26	Ras-induced ROS upregulation affecting cell proliferation is connected with cell type-specific alterations of HSF1/ <i>SESN3</i> /p21 ^{Cip1/WAF1} pathways. Cell Cycle, 2013, 12, 826-836.	1.3	46
27	Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene, 2012, 31, 1389-1397.	2.6	66
28	p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Letters, 2009, 276, 143-151.	3.2	92
29	Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 3. Inhibitory effect of SkQ1 on tumor development from p53-deficient cells. Biochemistry (Moscow), 2008, 73, 1300-1316.	0.7	82
30	Repression of Sestrin Family Genes Contributes to Oncogenic Ras-Induced Reactive Oxygen Species Up-regulation and Genetic Instability. Cancer Research, 2007, 67, 4671-4678.	0.4	123
31	Transformation by RAS oncogene decreases the width of substrate-spread fibroblasts but not their length. Cell Biology International, 2007, 31, 220-223.	1.4	8
32	ROS up-regulation mediates Ras-induced changes of cell morphology and motility. Experimental Cell Research, 2006, 312, 2066-2073.	1.2	70
33	Cell type-specific effects of asbestos on intracellular ROS levels, DNA oxidation and G1 cell cycle checkpoint. Oncogene, 2004, 23, 8834-8840.	2.6	34
34	The Protective Role of p53 in Ras-Induced Transformation of REF52 Cells. Molecular Biology, 2003, 37, 392-403.	0.4	5
35	A p53 mutation is required for stable transformation of REF52 cells by themyc andras oncogenes. Molecular Biology, 2000, 34, 277-285.	0.4	1
36	p53-dependent effects of RAS oncogene on chromosome stability and cell cycle checkpoints. Oncogene, 1999, 18, 3135-3142.	2.6	40

#	Article	IF	CITATIONS
37	Disruption of actin microfilaments by cytochalasin D leads to activation of p53. FEBS Letters, 1998, 430, 353-357.	1.3	75